failure. The limited number of trios included in our study did not allow us to do further stratification analyses (e.g. by cause of kidney disease). However, allele transmission did not differ from random after stratification by gender (data not shown).
In summary, Rippin et al. observed no association between the eNOS a/b polymorphism and the presence of overt nephropathy in Type 1 diabetic patients in a case-control study. We now present data from a family-based study showing no association between this marker and the development of chronic renal failure in patients with various causes of chronic renal disease. According to our observation, the hypothesis that the eNOS polymorphism represents a molecular mechanism leading to chronic renal failure, independent of causes, is highly unlikely. On the other hand, a minor role of this marker in particular subsets of renal patients with different causes of kidney disease cannot be excluded on the basis of our observations. tion in their article, we would also like to remark the importance of this mutation. The presence of this mutation in Spanish subjects was described by our group [2] and corroborated by another group in a British cohort [3] of Caucasian origin. The aim of our study was to investigate the presence of the amylin gene mutations in a group of 186 Spanish Type 2 diabetic patients and 130 non-diabetic subjects. We detected a single heterozygous mutation consisting of a G/A substitution at position −132 bp in 18 patients with Type 2 diabetes and in two (2) control subjects. The frequency of the G/A genotype was higher in diabetic patients, than in controls (9.7% vs 1.5%, p<0.005, odds ratio: 6.85, 95% CI: 1.56-30.08). Furthermore, studies of a family cohort (14 first-degree relatives belonging to eight families) detected the presence of the mutation in nine relatives, two of which were identified to be homozygous and having disturbed glucose metabolism. A similar screening approach was carried out on British subjects, where the −132 G/A mutation was detected in 5.3% of the diabetic patients, compared to 3.2% of the non-diabetic control group [3] . The same mutation has been reported in 4.1% of a Type 2 diabetic Danish cohort, compared with 7.1% non-diabetic controls [4] . Unlike our findings, no difference in the frequency of the −132 G/A variant was detected between these two groups, probably due to differences in the genetic background of the British and Danish cohorts.
Due to the high prevalence of this mutation in our study group (this mutation is located in the enhancer domain close to transcription-factor DNA-binding motifs), we hypothesised that this polymorphism confers increased IAPP promoter activity and could result in an increased expression and peptide se- (Table 1 ). In conclusion, we consider the amylin gene could play an important role in the complex heterogeneity of Type 2 diabetes, which also is highly related to the ethnic background.
